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Abstract 
We have demonstrated that 
bronchoalveolar lavage fluid from 
chronic obstructive pulmonary disease 
patients contains higher levels of 
interferon gamma compared to controls. 
Interferon gamma is a potent inducer of 
various cathepsins and matrix 
metalloproteases. Therefore, we 
postulated that interferon gamma could 
induce protease expression by 
macrophages in acute and chronic lung 
disease. Chronic obstructive pulmonary 
disease patients had greater levels of 
cathepsin S and matrix metalloprotease-
12 in their bronchoalveolar lavage fluid. 
Macrophages incubated with chronic 
obstructive pulmonary disease 
bronchoalveolar lavage fluid exhibited 
increased expression of cathepsin S and 
matrix metalloprotease-12, which was 
inhibited by the addition of interferon 
gamma neutralizing immunoglobulin. 
Human secretory leucocyte protease 
inhibitor is an 11.7 kDa cationic non-
glycosylated antiprotease synthesized and 
secreted by cells at the site of 
inflammation. We have demonstrated 
that secretory leucocyte protease inhibitor 
can inhibit interferon gamma-induced 
cathepsin S production by macrophages. 
Pre-treatment of macrophages with 
secretory leucocyte protease inhibitor 
inhibited interferon-gamma induced 
inhibitor kappa B beta degradation and 
activation of nuclear factor kappa B. 
Secretory leucocyte protease inhibitor 
may prove to be therapeutically 
important as a potential inhibitor of 
protease expression in chronic obstructive 
pulmonary disease. 
 
Chronic Obstructive Pulmonary 
Disease (COPD) is a major public health 
problem currently ranked as the fourth 
leading cause of death in the world (1). It is 
characterized by airflow limitation and is 
principally associated with exposure to 
cigarette smoke. However, the link between 
cigarette smoke, bronchial inflammation and 
the development of airflow limitation is not 
completely understood, as 15-20% of 
smokers develop COPD. One hypothesis is 
that individuals who develop exhibit an 
exaggerated inflammatory response to 
cigarette smoke COPD due to an immune 
system that is already primed by previous 
infections or by the possession of inherited 
genetic polymorphisms.  
A number of investigators have 
shown an increased numbers of T cells in 
the lungs of patients with COPD (2-4)   and 
that disease progression is linked to 
lymphocyte (T cell) infiltration. CD4+ and 
CD8+ T cells are increased in the airways 
and lung parenchyma of COPD patients (4). 
In addition, CD4+ and CD8+ T cells are 
activated with increased expression of IFN-γ 
in COPD patients (5).  
IFN-γ is produced by many cell 
types, including T-cells and B-cells, and is 
an important component of the anti-viral 
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response. It stimulates both macrophages 
and NK cells and is involved in the 
regulation of the immune and inflammatory 
responses. IFN-γ is also released 
predominantly by Th1 cells, and recruits 
leukocytes to a site of infection, resulting in 
increased inflammation. It activates 
macrophages for the expression of surface 
major histocompatibility class II antigens, 
costimulatory molecules, and inflammatory 
mediators for tumoricidal and antimicrobial 
activity. It regulates the proliferation and 
death of T lymphocytes, promotes the 
development of a type 1 T-helper cell 
response, and is essential for the control of 
many intracellular pathogens in vivo. IFN-γ 
mRNA or protein has been shown in mouse 
and human lung macrophages (6), spleen (7) 
bone marrow (8,9) , resting peritoneum (10) 
and peritoneal exudate following sterile 
inflammation (11).  
The primary families of proteases 
released into the extracellular space 
following cell activation include members of 
the serine protease, matrix metalloprotease 
(MMP) and cysteinyl cathepsin groups of 
proteases. Proteases play important roles in 
numerous biological processes and are 
capable of degrading many extracellular 
matrix components and as such are regarded 
as pivotal in the pathogenesis of COPD. 
MMPs are produced by a wide variety of 
cell types including epithelium, fibroblasts, 
neutrophils and macrophages. Several 
MMPs (including MMP-12) have been 
implicated in the pathogenesis of chronic 
lung injury, particularly in emphysema. This 
is shown in MMP-12 knockout mice, who 
do not develop air space enlargement in 
response to smoke exposure (12).  
Macrophages also synthesize 
cysteinyl cathepsins, which are ubiquitous 
lysosomal proteases (13-15). Cytokines and 
microbial products have previously been 
demonstrated to regulate cathepsin 
expression and activity (16,17) . IFN-γ has 
been shown to be a potent inducer of 
cathepsin S in monocytes and keratinocytes 
(18). IL-1 and TNF-α also induces cathepsin 
S activity, while exposure to IL-10 prevents 
conversion of pro-cathepsin S into its mature 
form (16). IL-13 has been shown to induce 
cathepsins B, H, K, L and S (19). We have 
shown previously that cathepsins cleave and 
inactivate key innate immunity proteins 
including human beta defensins 2 and 3 
(20), secretory leukocyte protease inhibitor 
(SLPI)  (21) and lactoferrin (22). 
SLPI is an 11.7-kD nonglycosylated 
protein produced at mucosal surfaces, 
primarily the upper respiratory tract (23) and 
is an important antiprotease (24). SLPI 
suppresses LPS-induced activation of NF-
κB, production of nitric oxide and TNF-α 
(25). Interestingly, IFN-γ can suppress 
expression of SLPI (26). In a model of acute 
lung injury, prior administration of SLPI 
attenuated pulmonary recruitment of 
neutrophils and decreased lung injury (27). 
We have recently shown that SLPI is taken 
up into monocytes and becomes distributed 
within the cytoplasm and nucleus and can 
bind NF-κB DNA binding regions within the 
IL-8 and TNF-α promoters (28). SLPI can 
also diminish p65 binding, thereby 
attenuating inflammation in monocytes (28).  
We postulated that COPD is 
associated with a Th1 cytokine profile with 
IFN-γ plays a central role in activity of 
macrophages leading to proteolysis of lung 
tissue. We further propose that SLPI could 
dampen this protease burden not by its direct 
antiprotease effect but by its anti-
inflammatory effects. To test this theory we 
investigated cytokine and protease levels in 
bronchoalveolar lavage fluid (BAL) fluid 
from control and COPD patients.  
Macrophage protease expression was also 
investigated following activation with IFN-γ 
stimuli and potential inhibition of protease 
expression induced by IFN-γ was evaluated 
in the presence of SLPI. The data from this 
study provide further evidence of an 
impaired protease/antiprotease balance in 
COPD patients due to a Th1 response that 
can be inhibited by SLPI. 
 
Experimental Procedures 
 
Culture and stimulation of monocyte cells - 
Myelomonocytic cells (U937) (European 
Collection of Cell Cultures Health 
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Protection Agency, Salisbury, Wiltshire, 
UK) (5 x 105 cells/ml) were cultured in 
RPMI 1640 medium (Gibco) and were 
differentiated to macrophage-like cells with 
PMA for 48 hours. The macrophage-like 
cells were incubated in fresh medium for a 
further two days before stimulation. 
Stimulation was performed with IFN-γ (R & 
D Systems, 10U/ng) for 3 or 24 hours before 
harvesting, for RNA or protein isolation, 
respectively. SLPI, Alpha-1 anti-trypsin 
(A1AT) and Elafin (each at 10µg/ml) 
stimulation was administered an hour prior 
to IFN-γ. Cells were also stimulated with 
BAL fluid from COPD patients for 2 hours, 
wash three times and resuspended in serum 
free medium for a further 48 hours. Mouse 
anti-IFN-γ (R&D Systems) (500ng/ml) or 
mouse IgG2A (R&D Systems) (500ng/ml) 
was incubated for 30 minutes at 37oC with 
COPD BAL fluid prior to cell stimulation. 
Cells were also treated for 1 hour with SN50 
and its inactive control, SN50M, 
(Calbiochem) prior to IFN-γ stimuli to block 
NF-κB activity.  
Isolation of PBMCs-Mononuclear cells were 
isolated from heparinised venous peripheral 
blood obtained from healthy volunteers 
using Lymphoprep™ (Nycomed, Norway). 
Briefly, freshly collected EDTA-peripheral 
blood samples (7.5mls) were diluted 1:1 in 
0.9% NaCl and 2 ml of 10% Dextran 
(Sigma) was added and incubated at RT for 
15 minutes. Afterwards the upper layer 
containing the mixed leukocyte fraction was 
removed and over-layered onto 5ml of 
Lymphoprep™. The sample was then 
centrifuged at 200 x g for 10 minutes. The 
mononuclear cell inter-phase band was 
aspirated and washed three times in HBSS 
medium. Monocytes were purified to 97% 
cell purity using the EasySep human CD14 
selection cocktail as recommended by 
manufactures (StemCell Technologies, 
London England). Monocytes were then 
cultured in RPMI containing 40% 
autologous serum, penicillin G (final 
concentration 100 U/ml), and streptomycin 
sulfate (final concentration 100 µg/ml) at 
37°C in a 5% CO2 atmosphere for 9 days 
(29). An hour prior to stimulation, cells were 
washed and incubated in serum-free 
medium.  
BAL fluid samples - Samples of BAL fluid 
and serum were obtained from subjects with 
COPD (n=17) and healthy volunteers 
(n=15). Ethical approval was obtained from 
Beaumont Hospital Ethics Committee and 
informed consent from each of the patients 
undergoing bronchoscopy. Subjects 
underwent flexible fiberoptic bronchoscopy 
and bronchoalveolar lavage (BAL) was 
performed. Samples were separated into cell 
suspension and supernatant.  
IFN-γ levels measured by sandwich ELISA - 
The concentration of IFN-γ was measured 
by ELISA using cytokine-specific Abs 
(R&D Systems, Abingdon, U.K.).  Values 
are expressed as picograms per ml.  
Semiquantitative reverse transcriptase 
polymerase chain reaction (RT-PCR) - After 
treatment with IFN-γ, cells were harvested 
in Tri reagent (Sigma-Ireland) and RNA was 
extracted as detailed in the manufacturer’s 
protocol. Total RNA (2 µg) was reverse-
transcribed at 37°C with 1 mM 
deoxynucleotide mix (Promega, 
Southampton, UK), 1.6 µg oligo-p[dT]15 
primer (Roche, Lewes, UK) and 1 µl M-
MLV  reverse transcriptase (Promega, 
Southampton, UK) in a 20 µl volume as 
described in the manufacturer’s protocol. 2 
µl of each cDNA was amplified with 1.25 U 
Taq DNA polymerase, 1×PCR buffer and 10 
mM dNTPs (Promega) in a 50 µl volume 
containing 100 pmol each of the following 
primers: 5′- ATG AAA CGG CTG GTT 
TGT GT-3′ and 5′-CTA GAT TTC TGG 
GTA AGA GGG AAA GCT AGC-3′ for 
cathepsin S; 5′- CTG GAC AAC TCA ACT 
CTG GCA A-3′ and 5′- ATT ATA GAT 
CCT GTA AGT GAG GTA CCG C-3′ for 
MMP-12; 5′- GAA GGT GAA GGT CGG 
AGT CA-3′ and 5′- TTC ACA CCC ATG 
ACG AAC AT-3′ for GAPDH; 5′- GCC 
GGG AAA TCG TGC GTG-3′ and 5′- GGG 
TAC ATG GTG GTG CCG-3′ for β-Actin  
PCR products were quantified 
densitometrically at cycle numbers between 
10 and 40 to determine the appropriate cycle 
number at which exponential amplification 
of products was occurring, and to identify 
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the cycle number at which sufficient 
discrimination was possible to accurately 
quantify increases or decreases in gene 
expression. After a hot start the 
amplification profile was 30 cycles of 1 min 
denaturation at 94°C, 1 min annealing at 
58°C and 1 min extension at 72°C for 
cathepsin S, MMP-12. GAPDH and β-Actin 
gene amplification required only 20 cycles. 
RT-PCR amplification of cathepsin S, 
MMP-12, β-Actin and GAPDH generated 
products of 1000 bp, 703 bp, 307 bp and 402 
bp respectively. PCR products were 
commercially sequenced (MWG Biotech 
AG, Ebersberg, Germany) to verify gene 
identity. PCR products were resolved on a 
1% (w/v) agarose gel containing 0.5 µg/ml 
ethidium bromide (Sigma). The ratio of PCR 
fragment intensities of each gene relative to 
GAPDH and β-Actin was determined by 
densitometry. 
Presence of cathepsin S - Cathepsin S 
activity was determined in supernatants 
from macrophage-like cells 24 hours after 
stimulation with or without IFN-γ or BAL 
fluid. Cathepsin S activity was determined 
in 100 µl of each BAL sample using the 
substrate Z-Phe-Arg-pNA (0.1 mM). The 
reaction buffer used for cathepsin S activity 
estimation was 0.2 M sodium acetate, pH 
7.5, 2mM ethylenediaminetetraacetic acid, 1 
mM dithiothreitol, 1 µM pepstatin, and 2 
mM Pefabloc. The samples were incubated 
with substrate for 60 min at 37°C, and 
fluorescence (substrate turnover) was 
determined by excitation at 355 nm and 
emission at 460 nm. Results were expressed 
as a change (delta) in fluorescence units 
over a 60-minute period (FU). 
Western blot - BAL fluid from healthy 
controls and COPD patients were 
investigated for the presence of MMP-12. 
Supernatant from U937 macrophages treated 
with IFN-γ were investigated for cathepsin S 
and MMP-12. BAL fluid or concentrated 
media from macrophage-like cells were 
separated by electrophoresis on 12% SDS-
polyacrylamide gels and transferred to a 
nitrocellulose membrane (Sigma-Aldrich) 
which was probed using mouse anti-MMP-
12 antibody (R&D Systems), rabbit anti-
cathepsin B antibody (Calbiochem) or 
mouse anti-cathepsin S antibody 
(Calbiochem). A rabbit anti-MMP-12 
(Calbiochem, Oncogene Research Products) 
antibody was used to detect MMP-12 from 
cells treated with COPD BAL fluid plus 
mouse anti-IFN-γ antibody or mouse 
IgG2A, to minimize antibody interaction. 
Binding was detected using the appropriate 
horseradish peroxidase-conjugated 
secondary antibodies and visualized by 
chemiluminescence (Pierce).  
Preparation of Subcellular Fractions - U937 
cells were activated with NE and nuclear and 
cytoplasmic extracts were isolated. Briefly 
cells were washed and resuspended in 1 ml 
of ice-cold PBS and kept on ice for 5 min. 
Cells were lifted from plates with a cell 
scraper and pelleted by centrifugation at 
10,000 rpm for 5 min at 4 °C. The 
supernatant was removed, and the cell pellet 
was resuspended in 1 ml of hypotonic buffer 
(10 mM Hepes (pH 7.9), 1.5 mM MgCl2, 
10 mM KCl, 0.5 mM PMSF, and 0.5 mM 
dithiothreitol) (Sigma). Cells were pelleted 
by centrifugation at 14,000 rpm for 10 min 
at 4 °C and then lysed for 10 min on ice in 
20 µl of hypotonic buffer containing 0.1% 
Igepal CA-630. Lysates were centrifuged as 
before, and the cytoplasmic extract was 
removed. The remaining nuclear pellet was 
lysed in 15 µl of lysis buffer (20 mM Hepes 
(pH 7.9), 420 mM NaCl, 1.5 mM MgCl2, 
0.2 mM EDTA, 25% (v/v) glycerol, 0.5 mM 
PMSF) (Sigma) for 15 min on ice. After 
centrifugation at 14,000 rpm for 10 min at 
4 °C, nuclear extracts were removed into 
35 µl of storage buffer (10 mM Hepes (pH 
7.9), 50 mM KCl, 0.2 mM EDTA, 20% 
(v/v) glycerol, 0.5 mM PMSF, and 0.5 mM 
dithiothreitol). Protein concentrations of 
cytoplasmic and nuclear extracts were 
determined, and extracts were stored at -
80 °C until required for use.  
NF-κB activity ELISA - The effect of IFN-γ 
and SLPI on NF-κB activity was determined 
using the TransAM NF-κB ELISA (Active 
Motif), using nuclear protein fractions.  
Densitometric analysis - Gels were analysed 
by densitometry and compared in a 
semiquantitative manner using the 
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GeneGenius Gel Documentation and 
analysis system (Cambridge, UK) and 
GeneSnap and GeneTools software. All 
expression values were verified by at least 
three independent experiments. 
Statistical analysis - Data were analyzed 
with the PRISM 3.0 software package 
(GraphPad, San Diego, CA). Results are 
expressed as the mean ± standard deviation 
(SD) and were compared by t test. 
Differences were considered significant at 
p≤0.05.  
 
RESULTS 
 
IFN-γ in COPD and effect on Protease 
Expression in Macrophages: IFN-γ levels in 
BAL fluid were determined by ELISA and 
were found to be significantly elevated in 
COPD individuals versus controls (72.85 ± 
28.61 versus 11.16 ± 6.19 pg/ml, p=0.0484) 
(Figure 1A). 
IFN-γ-induced protease mRNA 
expression was examined in U937 
macrophages. Macrophages were exposed to  
25 ng/ml IFN-γ for 3 hours. Cathepsin S and 
MMP-12 mRNA expression levels were 
investigated by RT-PCR (Figure 1B). IFN-γ 
significantly increased expression of 
cathepsin S and MMP-12 in U937 
macrophages (p=0.0147 and 0.0049 
respectively). The effect of IFN-γ 
stimulation on release of cathepsin S and 
MMP-12 from U937 macrophages was 
investigated. Elevated cathepsin S activity 
was observed when cells were stimulated 
with IFN-γ, using the cathepsin substrate Z-
Phe-Arg-AMC, at pH7.5 (Figure 1Ci). A 
statistically significant difference for 
cathepsin S activity between the control and 
cells stimulated with 10 ng/ml IFN-γ was 
observed (p=0.0013). This was further 
confirmed by Western blot, which 
demonstrated the increased production of 
cathepsin S by IFN-γ stimulated U937 
macrophages (Figure 1Cii).  
Western blot demonstrated that 
there was increased MMP-12 release from 
IFN-γ stimulated U937 macrophages (Figure 
1Cii). Increased MMP-9 activity was 
observed in U937 macrophages but was 
most likely due to the presence of small 
quantities of PMA in the cell medium (data 
not included). A change in MMP-9 activity 
was not observed when using similar 
experiments with PBM macrophages (data 
not included). 
IFN-γ induced Protease Expression: 
Neutrophil elastase (NE), cathepsin and 
MMP levels were measured in COPD 
and control BAL fluid. NE activity was 
not detected in COPD or control 
samples, however elevated cathepsin S 
activity was observed in COPD 
compared to control BAL fluid (Figure 
2A, p=0.0268). Western blot 
demonstrated the presence of MMP-12 
in COPD, but not control BAL fluid 
(Figure 2B). 
Levels of cathepsin S and MMP-12 
from U937 macrophages exposed to COPD 
BAL fluid were also evaluated. Elevated 
cathepsin S activity was observed when cells 
were stimulated with COPD BAL fluid 
compared to untreated cells (Figure 2C) 
(p=0.0011). An anti IFN-γ neutralizing 
antibody significantly inhibited this effect 
(p=0.0073) (Figure 2C). A mouse IgG2A 
antibody (isotype control) was also added to 
COPD BAL fluid and then to cells and was 
shown to have no inhibitory effects on the 
COPD BAL fluid induced cathepsin S 
production (p=0.8495). The increase in 
cathepsin S by COPD BAL fluid was further 
demonstrated by Western blot (Figure 2Di). 
COPD BAL fluid exposure also increased 
MMP-12 protein levels, demonstrated by 
Western blot (Figure 2Dii). The anti-IFN-γ 
antibody had the same inhibition effect on 
MMP-12 expression in macrophages 
exposed to COPD BAL fluid.   
Effect of SLPI on IFN-γ induced Protease 
Expression: IFN-γ-induced protease mRNA 
expression was further examined by the 
pretreatment of macrophages with SLPI 
prior to IFN-γ stimulation. U937 and PBM 
macrophages were exposed to 10µg/ml SLPI 
followed by 10ng/ml IFN-γ. Cathepsin S 
and 12 mRNA expression levels were 
investigated by RT-PCR from U937 
macrophages (Figure 3A). IFN-γ 
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significantly increased expression of 
cathepsin S and MMP-12 even at 10ng/ml 
IFN-γ. SLPI significantly decreased the gene 
expression of cathepsin S (p= 0.0061). A 
reduced level of cathepsin S activity was 
observed when U937 (Figure 3B) and PBM 
(Figure 3D) macrophages were incubated 
firstly with SPLI follow by IFN-γ, using the 
cathepsin substrate Z-Phe-Arg-AMC, at 
pH7.5. A statistically significant decrease in 
cathepsin S activity was observed between 
cells stimulated with 10 ng/ml IFN-γ and 
cells incubated with SLPI and IFN-γ 
(p=0.0229 and 0.023 for U937s and PBM, 
respectively). Exposing U937 macrophages 
to A1AT or elafin prior to IFN-γ stimulation 
had no significant effect on IFN-γ –induced 
cathepsin S activity (Figure 3B). No 
reduction in MMP-12 was observed when 
U937 (Figure 3C) and PBM macrophages 
(Figure 3D) were incubated firstly with 
SPLI follow by IFN-γ.  
Effect of SLPI on IFN-γ signalling pathways 
in Macrophages: SLPI inhibited IFN-γ –
induced Iκ-Bβ degradation (Figure 4A). 
Similarly NF-κB activation was observed 
after 3 hours in the presence of IFN-γ 
(Figure 4B) and IFN-γ -induced NF-κB 
nuclear translocation was increased 2-fold 
compared with control. IFN-γ -induced NF-
κB activation was also inhibited by SLPI.  
SN50, a cell-permeable peptide that 
inhibits NF-κB nuclear translocation 
downstream of IKK, and its mutant peptide, 
NF-κB SN50M, were used to investigate 
whether inhibition of NF-κB could reduce 
IFN-γ -induced protease expression. SN50 
was able to inhibit IFN-γ -induced cathepsin 
S (Figure 4C, P=0.022) demonstrating that 
IFN-γ signals via NF-κB to induce cathepsin 
S expression in macrophages.  
 
DISCUSSION 
 
Proteases have been implicated in COPD as 
a cause of airway inflammation and 
parenchymal destruction (2,30). Although a 
prominent role for NE has been postulated 
in COPD for many years, recent work has 
demonstrated that cathepsins and matrix 
metalloproteases, produced primarily by 
macrophages, are also important (31). In 
addition to macrophages and neutrophils as 
modulators of inflammation in COPD, an 
increasing number of authors have described 
an important role for lymphocytes (2-4,32). 
We postulated that increased IFN-γ 
observed in COPD would induce expression 
of these proteases (cathepsins and MMPs). 
This study demonstrates significantly 
elevated levels of IFN-γ, cathepsin S and 
MMP-12 in COPD BAL fluid compared to 
control BAL fluid We have further 
demonstrated that incubation of 
macrophages with IFN-γ leads to increased 
cathepsin S and MMP–12 expression and 
that the neutralization of IFN-γ activity in 
COPD BAL fluid decreases COPD BAL 
fluid-induced cathepsin S and MMP-12 
expression by macrophages. Finally, we 
have demonstrated that SLPI can down-
regulate IFN-γ-induced protease production, 
via inactivation of the NF-κB signaling 
pathway. Therefore, these studies provide 
molecular and clinical data to support the 
view that IFN-γ up-regulation leads to 
expression of proteases responsible for lung 
tissue damage in COPD and that this is 
remediable by the anti-inflammatory effects 
of SLPI. 
Both CD4+ and CD8+ T cells are 
increased in the COPD lung, with CD8+ 
cells being predominant (33) evidence that 
COPD is predominantly a Th1 driven 
condition.  In general, Th1 responses 
preferentially stimulate genes that are 
involved in apoptosis and tissue injury (34).  
The Th1 cells observed in COPD are the 
major potential source of IFN-γ in the lungs. 
It has been shown that some of the 
mediators involved in the inflammatory 
process observed in emphysematous tissues 
can directly induce emphysema. IFN-γ is 
one of those candidates. Transgenic over-
expression of IFN-γ in the adult murine lung 
results in pulmonary emphysema (35). BAL 
fluids from the over-expressing IFN-γ mice 
have increased neutrophil and lymphocyte 
levels and an exaggerated number of 
macrophages compared with controls (35). 
Elevated levels of IFN-γ alter the pulmonary 
protease/antiprotease balance in a 
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proteolytic direction via the induction of 
MMPs and a variety of cathepsins (35). 
Production of high amounts of IFN-γ (~20 
ng/ml) has been reported with dendritic cell 
populations after stimulation with IL-12/IL-
18 (7,36,37). 
In this study cathepsin S and MMP-
12 gene expressions and protein activity 
were increased in macrophages exposed to 
IFN-γ. This increase in proteases can have a 
major impact on innate host defences in the 
lung, as we have previously shown that 
cathepsin S can cleave and inactivate human 
β-defensin 2 and 3 (21), SLPI (21) and 
lactoferrin (23). The cleavage of SLPI by 
cathepsin S results in the loss of the active 
site of SLPI and the inactivation of SLPI 
anti-neutrophil elastase capacity, further 
worsening the potential protease burden. 
IFN-γ also down-regulates SLPI (26,38) via 
CCR-5 and we have previously shown 
decreased levels of SLPI in the COPD lung 
mediated in part by cathepsin degradation 
(21). Cathepsin S has been identified as the 
dominant endocytic protease that is 
specifically upregulated under inflammatory 
conditions in the presence of IFN-γ (39). 
Cathepsin S upregulation in COPD is 
extremely relevant in the context of recent 
data showing that cathepsin S inhibition 
(and a null mutation of cathepsin S) 
decreases IFN-γ-induced DNA injury, 
apoptosis, emphysema, inflammation, and 
protease accumulation in a murine 
pulmonary emphysema modeling system 
(40).  
MMP-12 has also been implicated 
the pathogenesis of chronic lung injury, 
particularly emphysema. MMP–12 is 
elevated in the lungs of COPD patients (31). 
Interestingly, MMP-12 knockout mice do 
not develop air space enlargement in 
response to smoke exposure, implicating 
MMP-12 in development of cigarette smoke 
induced emphysema (12). The increased 
expression of this important MMP in our 
study driven by IFN-γ is therefore of 
interest.  
SLPI possesses anti-inflammatory 
activity (41). LPS hyporesponsive cells 
transcribe SLPI and transfection of 
macrophages with SLPI suppresses LPS-
induced activation of NF-κB, production of 
nitric oxide and TNF-α by an unknown 
mechanism (25). IFN-γ can suppress 
expression of SLPI and restore LPS 
responsiveness to SLPI-producing cells (25). 
We have previously shown that SLPI can 
inhibit LPS and lipoteichoic acid (LTA)-
induced NF-κB activation in monocytic cells 
by preventing degradation of key regulatory 
proteins, like IκBα and IκBβ (42,43). SLPI 
prevents the degradation of IκBα and β 
without affecting IκBα phosphorylation and 
ubiquitination (42). SLPI inhibition of IFN-
γ-induced IκBβ degradation and NF-κB 
activation is due to the anti-inflammatory 
activity of SLPI (28). SLPI’s ability to 
inhibit IFN-γ-induced NF-kB activation also 
resulted in decreased cathepsin S expression 
but not MMP-12 production. SLPI’s 
inability to inhibit IFN-γ-induced MMP-12 
may be due in part to activation of MMP-12 
expression via another transcription factor 
pathway other than NF-κB.  Recently, 
Churg et al. have demonstrated that another 
anti-protease, A1AT, can inhibit cigarette 
smoke induced MMP-12 and TNF-α via 
inactivation of PAR-1 by inhibiting 
thrombin and plasmin (44). This further 
demonstrates the important anti-
inflammatory functions of classically 
described anti-proteases. Further 
investigation of the interaction of SLPI with 
the IFN-γ pathway would be beneficial. 
In conclusion, we have 
demonstrated that a Th1 response leads to 
increased production of a spectrum of 
proteases driven by IFN-γ. Inhibition of 
IFN-γ in COPD BAL fluid inhibits this 
process. Therefore, by minimizing the IFN- 
induced protease expression, SLPI is of 
potential therapeutic relevance in the 
treatment of COPD.  
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FIGURE LEGENDS 
 
 
Fig. 1. IFN-γ levels in control and COPD patients and IFN-γ effect on protease production in 
U937s. (A) IFN-γ levels in COPD and controls. (B) RT-PCR was carried out on mRNA from 
differentiated U937 cells treated with IFN-γ to amplify regions of the cathepsin S, MMP-12, 
GAPDH and β-Actin genes. The quantification of the expression of cathepsin S and MMP-12 was 
assessed compared to β-Actin and GAPDH from U937 macrophages. (C) Cathepsin S activity 
was determined using the Z-Phe-Arg-AMC substrate (pH 7.5).  (D) Western blot analysis for 
cathepsin S (36 kDa) and MMP-12 (45 kDa) levels in supernatants recovered from U937 
macrophages exposed to IFN-γ. Protein loading was corrected for sample protein concentrations. 
Experiments were performed at least 3 times and representative data and SE are shown. A 
statistical significance is highlighted with its appropriate p value. 
 
Fig. 2. Protease profile from control and COPD BAL fluid and macrophages exposed to COPD 
BAL fluid. (A) Cathepsin S activity from control and COPD BAL fluid was determined using the 
Z-Phe-Arg-pNA substrate (pH 7.5).  (B) MMP-12 Western blot of control and COPD BAL fluid.  
The 22 kDa bands represent the catalytic domain of human MMP-12. (A) Cathepsin S activity 
was determined after 24 hours following a 2-hour stimulation with COPD BAL fluid or COPD 
BAL fluid plus anti IFN-γ or isotype control. A statistical significance is highlighted with its 
appropriate p value.  (D) Western blot analysis for cathepsin S (i) and MMP-12 (ii) levels in 
supernatants recovered from U937 macrophages exposed to COPD BAL fluid or COPD BAL 
fluid plus anti IFN-γ/isotype control antibody. Protein loading was corrected for sample protein 
concentrations. Experiments were performed at least 3 times and representative data and SE are 
shown. 
 
Fig. 3. Inhibitory effects of SLPI on IFN-γ induced protease gene expression and protein release. 
(A) RT-PCR was carried out on mRNA from differentiated U937 cells treated with SLPI, IFN-γ 
and SLPI followed by IFN-γ to amplify regions of the cathepsin S, -12, β-Actin and GAPDH 
genes. The quantification of the expression of cathepsin S and -12 was assessed compared to β-
Actin and GAPDH from U937 macrophages. (B) Cathepsin S activity was determined after 24 
hours following incubation of U937s with IFN-γ, antiprotease (SLPI, elafin or A1AT) or pre-
incubation with an antiprotease followed by IFN-γ. (C) MMP-12 levels were examined after 
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incubation of U937s with IFN-γ, SLPI or SLPI followed by IFN-γ. (D) Cathepsin S activity was 
determined 24 hours after incubating PBM-derived macrophages with IFN-γ, SLPI or SLPI 
followed by IFN-γ. (E) MMP-12 levels were examined after incubating PBM-derived 
macrophages with IFN-γ, SLPI or SLPI followed by IFN-γ. Protein loading was corrected for 
sample protein concentrations. Experiments were performed at least 3 times and representative 
data and SE are shown. 
 
Fig. 4. SLPI inhibits IFN-γ–induced NF-κB activation. (A) Iκ-Bβ degradation was analyzed by 
Western blot using an anti-Iκ-Bβ antibody and cytosolic extracts (10 µg) from control (-), IFN-γ –
treated, SLPI-treated or IFN-γ/SLPI-treated macrophages (10 ng/ml IFN-γ, 180 minutes). (B) NF-
κB activation was measured using the TransAM NF-κB activity ELISA in nuclear extracts (2 µg) 
from control (-) and IFN-γ-treated macrophages (10 ng/ml, 180 minutes) +/- SLPI (10µg/ml). (C) 
Cathepsin S activity was determined using the Z-Phe-Arg-AMC substrate 24 hours after 
stimulation with IFN-γ. Cells were treated for 60 minutes with SN50 (1µg/ml) and its inactive 
control (SN50M) (Calbiochem), prior to treated macrophages with IFN-γ (10 ng/ml), to block 
NF-κB activity. Protein loading was corrected for sample protein concentrations. Experiments or 
analyses of results were performed at least 3 times and representative data and SE are shown. 
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